---
document_datetime: 2025-12-02 06:50:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme.html
document_name: nexviadyme.html
version: success
processing_time: 0.1201189
conversion_datetime: 2025-12-26 18:59:17.422098
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nexviadyme

[RSS](/en/individual-human-medicine.xml/67477)

##### Authorised

This medicine is authorised for use in the European Union

avalglucosidase alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nexviadyme](#news-on)
- [More information on Nexviadyme](#more-information-on-nexviadyme-942)
- [More information on Nexviadyme](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Nexviadyme is an enzyme replacement therapy used to treat patients with Pompe disease, a rare inherited disorder caused by the lack of an enzyme called alpha-glucosidase. Patients with Pompe disease have a build-up of glycogen (complex sugars) in body tissues, including the heart, lung and skeletal muscles, causing enlarged heart, breathing difficulties and muscle weakness.

Nexviadyme contains the active substance avalglucosidase alfa.

Expand section

Collapse section

## How is Nexviadyme used?

Nexviadyme treatment should be supervised by a doctor who has experience managing patients with Pompe disease or other inherited diseases of the same type.

Nexviadyme is given as an infusion (drip) into a vein once every two weeks, and the dose depends on the patient's body weight. A doctor may decide to increase the dose for patients with infantile-onset Pompe disease (Pompe disease that appears at an early age) who do not improve with the regular dose. Patients who have no major side effects with the first few infusions may be able to have their infusions given at home.

For more information about using Nexviadyme, see the package leaflet or contact your doctor or pharmacist.

## How does Nexviadyme work?

The active substance in Nexviadyme, avalglucosidase alfa, is a version of the enzyme alpha-glucosidase, which is lacking in people with Pompe disease. Alpha-glucosidase breaks down glycogen into glucose that can be used for energy by the body's cells. If the enzyme is not present, glycogen builds up in certain tissues, including the heart and diaphragm (the main breathing muscle under the lungs), causing damage to them. By replacing the missing enzyme, avalglucosidase alfa helps break down glycogen and stop it from building up and causing the symptoms of the condition.

## What benefits of Nexviadyme have been shown in studies?

One main study involving 100 patients between 16 and 78 years of age with Pompe disease showed that Nexviadyme was at least as effective in improving lung function as another replacement therapy for Pompe disease (alglucosidase alfa). The patients' lung function was measured as the percentage change in their forced vital capacity (FVC, the maximum amount of air exhaled forcefully in one breath).

In the study, patients receiving Nexviadyme for 49 weeks increased their lung function by 2.9% compared with patients receiving alglucosidase alfa, who increased their lung function by 0.5%.

## What are the risks associated with Nexviadyme?

The most common side effects with Nexviadyme are hypersensitivity (allergic) reactions and infusion-associated reactions, which may affect more than 1 in 4 people; severe allergic reactions (anaphylaxis) have been reported in less than 2 in 100 people. Other frequently reported side effects (in up to 1 in 10 people) are itching, rash, headache, urticaria (itchy rash), tiredness, nausea (feeling sick), and chills. For the full list of side effects and restrictions of Nexviadyme, see the package leaflet.

## Why is Nexviadyme authorised in the EU?

A main study showed that Nexviadyme improved the lung function of patients with Pompe disease. The most common side effects are allergic and infusion reactions and are comparable to those reported in patients treated with similar medicines.

The European Medicines Agency, therefore, decided that Nexviadyme's benefits are greater than its risks, and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Nexviadyme?

The company that markets Nexviadyme will provide educational material for healthcare professionals including guidance on how to monitor patients for risk of infection and how to arrange infusions at home.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nexviadyme have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Nexviadyme are continuously monitored. Suspected side effects reported with Nexviadyme are carefully evaluated and any necessary action taken to protect patients.

Nexviadyme : EPAR - Medicine overview

Reference Number: EMA/429680/2021

English (EN) (121.67 KB - PDF)

**First published:** 27/07/2022

[View](/en/documents/overview/nexviadyme-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-107)

български (BG) (146.91 KB - PDF)

**First published:**

27/07/2022

[View](/bg/documents/overview/nexviadyme-epar-medicine-overview_bg.pdf)

español (ES) (122.63 KB - PDF)

**First published:**

27/07/2022

[View](/es/documents/overview/nexviadyme-epar-medicine-overview_es.pdf)

čeština (CS) (143.67 KB - PDF)

**First published:**

27/07/2022

[View](/cs/documents/overview/nexviadyme-epar-medicine-overview_cs.pdf)

dansk (DA) (120.63 KB - PDF)

**First published:**

27/07/2022

[View](/da/documents/overview/nexviadyme-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.06 KB - PDF)

**First published:**

27/07/2022

[View](/de/documents/overview/nexviadyme-epar-medicine-overview_de.pdf)

eesti keel (ET) (109.04 KB - PDF)

**First published:**

27/07/2022

[View](/et/documents/overview/nexviadyme-epar-medicine-overview_et.pdf)

ελληνικά (EL) (147.12 KB - PDF)

**First published:**

27/07/2022

[View](/el/documents/overview/nexviadyme-epar-medicine-overview_el.pdf)

français (FR) (124.18 KB - PDF)

**First published:**

27/07/2022

[View](/fr/documents/overview/nexviadyme-epar-medicine-overview_fr.pdf)

hrvatski (HR) (144.7 KB - PDF)

**First published:**

27/07/2022

[View](/hr/documents/overview/nexviadyme-epar-medicine-overview_hr.pdf)

italiano (IT) (121.38 KB - PDF)

**First published:**

27/07/2022

[View](/it/documents/overview/nexviadyme-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (158.85 KB - PDF)

**First published:**

27/07/2022

[View](/lv/documents/overview/nexviadyme-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (141.37 KB - PDF)

**First published:**

27/07/2022

[View](/lt/documents/overview/nexviadyme-epar-medicine-overview_lt.pdf)

magyar (HU) (145.49 KB - PDF)

**First published:**

27/07/2022

[View](/hu/documents/overview/nexviadyme-epar-medicine-overview_hu.pdf)

Malti (MT) (147.53 KB - PDF)

**First published:**

27/07/2022

[View](/mt/documents/overview/nexviadyme-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.61 KB - PDF)

**First published:**

27/07/2022

[View](/nl/documents/overview/nexviadyme-epar-medicine-overview_nl.pdf)

polski (PL) (146.7 KB - PDF)

**First published:**

27/07/2022

[View](/pl/documents/overview/nexviadyme-epar-medicine-overview_pl.pdf)

português (PT) (123.08 KB - PDF)

**First published:**

27/07/2022

[View](/pt/documents/overview/nexviadyme-epar-medicine-overview_pt.pdf)

română (RO) (150.79 KB - PDF)

**First published:**

27/07/2022

[View](/ro/documents/overview/nexviadyme-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143 KB - PDF)

**First published:**

27/07/2022

[View](/sk/documents/overview/nexviadyme-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.64 KB - PDF)

**First published:**

27/07/2022

[View](/sl/documents/overview/nexviadyme-epar-medicine-overview_sl.pdf)

Suomi (FI) (119.05 KB - PDF)

**First published:**

27/07/2022

[View](/fi/documents/overview/nexviadyme-epar-medicine-overview_fi.pdf)

svenska (SV) (119.76 KB - PDF)

**First published:**

27/07/2022

[View](/sv/documents/overview/nexviadyme-epar-medicine-overview_sv.pdf)

Nexviadyme : EPAR - Risk-management-plan summary

English (EN) (171.15 KB - PDF)

**First published:** 27/07/2022

[View](/en/documents/rmp-summary/nexviadyme-epar-risk-management-plan-summary_en.pdf)

## Product information

Nexviadyme : EPAR - Product Information

English (EN) (359.98 KB - PDF)

**First published:** 27/07/2022

**Last updated:** 08/08/2024

[View](/en/documents/product-information/nexviadyme-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-400)

български (BG) (649.01 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/bg/documents/product-information/nexviadyme-epar-product-information_bg.pdf)

español (ES) (490.03 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/es/documents/product-information/nexviadyme-epar-product-information_es.pdf)

čeština (CS) (493.78 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/cs/documents/product-information/nexviadyme-epar-product-information_cs.pdf)

dansk (DA) (486.75 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/da/documents/product-information/nexviadyme-epar-product-information_da.pdf)

Deutsch (DE) (490.33 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/de/documents/product-information/nexviadyme-epar-product-information_de.pdf)

eesti keel (ET) (494 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/et/documents/product-information/nexviadyme-epar-product-information_et.pdf)

ελληνικά (EL) (634.86 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/el/documents/product-information/nexviadyme-epar-product-information_el.pdf)

français (FR) (583.5 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/fr/documents/product-information/nexviadyme-epar-product-information_fr.pdf)

hrvatski (HR) (543.83 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/hr/documents/product-information/nexviadyme-epar-product-information_hr.pdf)

íslenska (IS) (494.61 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/is/documents/product-information/nexviadyme-epar-product-information_is.pdf)

italiano (IT) (591.35 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/it/documents/product-information/nexviadyme-epar-product-information_it.pdf)

latviešu valoda (LV) (524.13 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/lv/documents/product-information/nexviadyme-epar-product-information_lv.pdf)

lietuvių kalba (LT) (491.75 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/lt/documents/product-information/nexviadyme-epar-product-information_lt.pdf)

magyar (HU) (576.59 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/hu/documents/product-information/nexviadyme-epar-product-information_hu.pdf)

Malti (MT) (670.16 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/mt/documents/product-information/nexviadyme-epar-product-information_mt.pdf)

Nederlands (NL) (515.15 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/nl/documents/product-information/nexviadyme-epar-product-information_nl.pdf)

norsk (NO) (503.58 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/no/documents/product-information/nexviadyme-epar-product-information_no.pdf)

polski (PL) (575.58 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/pl/documents/product-information/nexviadyme-epar-product-information_pl.pdf)

português (PT) (591.43 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/pt/documents/product-information/nexviadyme-epar-product-information_pt.pdf)

română (RO) (532.76 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/ro/documents/product-information/nexviadyme-epar-product-information_ro.pdf)

slovenčina (SK) (604.4 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/sk/documents/product-information/nexviadyme-epar-product-information_sk.pdf)

slovenščina (SL) (584.66 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/sl/documents/product-information/nexviadyme-epar-product-information_sl.pdf)

Suomi (FI) (555.15 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/fi/documents/product-information/nexviadyme-epar-product-information_fi.pdf)

svenska (SV) (566.34 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

08/08/2024

[View](/sv/documents/product-information/nexviadyme-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0018 06/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nexviadyme : EPAR - All Authorised presentations

English (EN) (44.21 KB - PDF)

**First published:** 27/07/2022

[View](/en/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-980)

български (BG) (54.99 KB - PDF)

**First published:**

27/07/2022

[View](/bg/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.68 KB - PDF)

**First published:**

27/07/2022

[View](/es/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.64 KB - PDF)

**First published:**

27/07/2022

[View](/cs/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.51 KB - PDF)

**First published:**

27/07/2022

[View](/da/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (35.96 KB - PDF)

**First published:**

27/07/2022

[View](/de/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.31 KB - PDF)

**First published:**

27/07/2022

[View](/et/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.41 KB - PDF)

**First published:**

27/07/2022

**Last updated:**

24/07/2024

[View](/el/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_el.pdf)

français (FR) (47.82 KB - PDF)

**First published:**

27/07/2022

[View](/fr/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (44.2 KB - PDF)

**First published:**

27/07/2022

[View](/hr/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.47 KB - PDF)

**First published:**

27/07/2022

[View](/is/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.67 KB - PDF)

**First published:**

27/07/2022

[View](/it/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (72.06 KB - PDF)

**First published:**

27/07/2022

[View](/lv/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (86.93 KB - PDF)

**First published:**

27/07/2022

[View](/lt/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.22 KB - PDF)

**First published:**

27/07/2022

[View](/hu/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.88 KB - PDF)

**First published:**

27/07/2022

[View](/mt/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.13 KB - PDF)

**First published:**

27/07/2022

[View](/nl/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.34 KB - PDF)

**First published:**

27/07/2022

[View](/no/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_no.pdf)

polski (PL) (71.15 KB - PDF)

**First published:**

27/07/2022

[View](/pl/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.96 KB - PDF)

**First published:**

27/07/2022

[View](/pt/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.91 KB - PDF)

**First published:**

27/07/2022

[View](/ro/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (46.3 KB - PDF)

**First published:**

27/07/2022

[View](/sk/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.83 KB - PDF)

**First published:**

27/07/2022

[View](/sl/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.85 KB - PDF)

**First published:**

27/07/2022

[View](/fi/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.6 KB - PDF)

**First published:**

27/07/2022

[View](/sv/documents/all-authorised-presentations/nexviadyme-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nexviadyme Active substance avalglucosidase alfa International non-proprietary name (INN) or common name avalglucosidase alfa Therapeutic area (MeSH) Glycogen Storage Disease Type II Anatomical therapeutic chemical (ATC) code A16

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).

## Authorisation details

EMA product number EMEA/H/C/005501

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Sanofi B.V.

Paasheuvelweg 25

Opinion adopted 11/11/2021 Marketing authorisation issued 24/06/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nexviadyme : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (117.58 KB - PDF)

**First published:** 05/04/2023

**Last updated:** 08/08/2024

[View](/en/documents/procedural-steps-after/nexviadyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Nexviadyme : EPAR - Orphan Maintenance Assessment Report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000048959

English (EN) (793.84 KB - PDF)

**First published:** 02/08/2022

[View](/en/documents/orphan-maintenance-report/nexviadyme-epar-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Nexviadyme : EPAR - Public assessment report

Adopted

Reference Number: EMA/708926/2021

English (EN) (6.32 MB - PDF)

**First published:** 27/07/2022

[View](/en/documents/assessment-report/nexviadyme-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nexviadyme

Adopted

Reference Number: EMA/CHMP/631749/2021 Rev.2

English (EN) (170.38 KB - PDF)

**First published:** 23/07/2021

**Last updated:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nexviadyme_en.pdf)

#### News on Nexviadyme

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021) 23/07/2021

#### More information on Nexviadyme

Pompe disease is rare and Nexviadyme was [designated an 'orphan medicine'](/en/medicines/human/orphan-designations/eu-3-14-1251) (a medicine used in rare diseases) on 26 March 2014.

This product is no longer an orphan medicine. It was originally designated an orphan medicine on 26 March 2014. Nexviadyme was withdrawn from the Community register of orphan medicinal products by the European Commission in April 2022 at the time of the granting of a marketing authorisation.

#### More information on Nexviadyme

- [A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study - post-authorisation study](https://catalogues.ema.europa.eu/study/107473)

**This page was last updated on** 08/08/2024

## Share this page

[Back to top](#main-content)